by Isogenica Webmaster | Jul 2023 | Press Releases
University of Leicester strikes partnership with biotech experts Isogenica to develop personalised cancer treatments Patients could benefit from bespoke cancer-fighting treatments with fewer side effects thanks to a new partnership between a biotech...
by Isogenica Webmaster | Mar 2023 | Press Releases
Isogenica and Frederick National Laboratory for Cancer Research add two more projects to their contractual relationship Announcing a further collaboration with the Frederick National Laboratory for Cancer Research The relationship between Isogenica and...
by Isogenica Webmaster | Jan 2023 | Press Releases
Arvinas teams up with Isogenica using our CIS display technology to expand their PROTAC® platform Announcing a new collaboration with Arvinas Isogenica is pleased to announce a technology license agreement with Arvinas, who will leverage Isogenica’s CIS Display...
by Philippa Shelton | Nov 2022 | Press Releases, Welcome
Isogenica and Frederick National Laboratory for Cancer Research team up to discover novel antibody therapeutics Announcing a new collaboration with the Frederick National Laboratory for Cancer Research UK-based antibody engineering experts Isogenica are proud... by Philippa Shelton | May 2022 | Press Releases
Wellmarker Bio signs MoU with Isogenica for the development of multiple therapeutic assets The MoU will serve as a foundation for increased cooperation between the two companies Wellmarker Bio (WMBIO) and Isogenica today announced the signing of a Memorandum of... by Mandeep Sehmi | Apr 2022 | Press Releases
Isogenica-Phenotypeca Further Collaboration through Medilink Award Isogenica-Phenotypeca collaboration spear-headed by SMART Grant award Read the Press Release Isogenica are furthering their collaboration with Phenotypeca, whose platform will deploy...